New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
20:08 EDTHEBHemispherx fatigue drug Ampligen rejected for approval, WSJ reports
An FDA panel voted 8-to-5 against approval of Hemixpherx's (HEB) chronic fatigue drug Ampligen at an FDA Arthritis Advisory Committee Meeting Thursday, according to a Wall Street Journal report. Reference Link
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
09:27 EDTHEBHemispherx says Ampligen blocks certain Ebola Viral Disease protein
Hemispherx Biopharma announced that it had received a new research report from Professor Tramontano in the Department of Life and Environmental Sciences, University of Cagliari, Italy. The biochemical study demonstrates Ampligen can successfully bind to the lethal EVD viral protein designated VP35. Experiments being conducted establish the scientific foundation for Ampligen, an experimental drug, as a potential preventive and early onset therapeutic for Ebola, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use